J. Šmíd

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Jan van den Berg, Louis B. Bartels, H. Heidbuchel, 2022, The Lancet.

(Atrial fibrillation as risk factor in patients after cardiac arrest for ventricular fibrillation)

R. Rokyta, V. Vancura, J. Šmíd, 2022, Cor et Vasa.

Five-year outcomes in cardiac surgery patients with atrial fibrillation undergoing concomitant surgical ablation versus no ablation. The long-term follow-up of the PRAGUE-12 Study.

P. Widimsky, R. Hatala, P. Červinka, 2019, Heart rhythm.

Atrial fibrillation and its relation to cardiac diseases and sudden cardiac death

R. Rokyta, J. Šmíd, 2017 .

Atrial fi brillation and its relation to cardiac diseases and sudden cardiac death )

J. Šmíd, 2017 .

The variability of automated QRS duration measurement

Marek Brabec, M. Brabec, Dan Wichterle, 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.

Jan van den Berg, Louis B. Bartels, H. Heidbuchel, 2022, Lancet.